Project Grant R01AG088637

Award Date 5/15/25
Completion Date 1/31/30
Dollars Obligated $455K
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $327,500 to The Johns Hopkins University to develop novel tree-based statistical methods and algorithms for identifying time-dynamic and personalized biomarker subgroups at high risk for cognitive decline due to Alzheimer's disease (AD). The 2-year project aims to leverage longitudinal biomarker data and risk/protective factors from the Preclinical AD Consortium to construct classification and...
The National Institute on Aging (NIA) awarded a $366,648 Project Grant (CFDA 93.866 - Aging Research) to New York University (NYU) to develop statistical methods for accurate estimation and prediction in Alzheimer's disease (AD) progression. The project aims to: 1) Enable the use of clinically relevant time origins through proper adjustment for truncation in longitudinal cohort studies; 2) Develop methods to adjust for censored or "cured" covariates and yield accurate estimates of...
This Project Grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), provides $2,251,070 to the University of California Irvine through July 2025. The grant supports research to develop new statistical methodologies for analyzing Alzheimer's disease data from longitudinal cohort studies. Key deliverables include methods for assessing prediction precision for recurrent event survival data using time-dependent ROC and C-index...
This $301,417 federal Project Grant award, provided by the National Institute on Aging under CFDA 93.866 Aging Research, aims to develop innovative analytical methods and software tools for integrating and synthesizing data from Alzheimer's disease and related dementias (AD/ADRD) research studies. The key objectives are to: 1) Create new approaches for modeling and addressing inconsistencies in the evidence from network meta-analyses of AD/ADRD interventions, and 2) Develop novel network...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $372,690 to the University of California, Berkeley to conduct research aimed at understanding the heterogeneous causal pathophysiology of Alzheimer's disease (AD). The key objectives are to: 1) Develop new statistical methods for uncovering heterogeneous causal relationships among amyloid-beta, tau accumulation, and cognition across diverse AD datasets; 2) Apply these methods to reveal optimal...
This $766,467 Project Grant award was provided by the National Institute on Aging (NIA) under the Aging Research Federal Grant Program (CFDA 93.866) to the Georgia State University Research Foundation Inc. The funding supports the development of flexible multivariate models that can jointly analyze multi-scale neuroimaging and genomic data to better understand Alzheimer's disease and related dementias (ADRD). The proposed models aim to address key limitations of existing multivariate data fusion...
This $287,118 Project Grant was awarded on September 1, 2023 by the National Institute on Aging (NIA) under the Aging Research (CFDA 93.866) grant program. The grant will fund the development of techniques to use deep transfer learning and multimodal data, including brain MRIs, genetic information, and cognitive tests, to enable the early detection and forecasting of Alzheimer's disease progression. The University of Massachusetts (UMass), as the prime awardee, will create an end-to-end...
This Project Grant award, valued at $131,813, was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The award will fund research by the Trustees of Boston University, doing business as Boston University Medical Campus, to quantify the effects of poverty alleviation policies, such as the Supplemental Nutrition Assistance Program (SNAP), on the prevalence and disparities of Alzheimer's disease and related dementias (AD/ADRD). The...
This federal Project Grant award of $2,494,096 from the National Institute on Aging's Aging Research program (CFDA 93.866) will fund research to develop an early detection and monitoring approach for cognitive changes related to Alzheimer's disease. The project aims to leverage web-based cognitive testing to capture high-resolution multi-day learning curves that may detect subtle preclinical memory changes. The primary awardee, Brigham & Women's Hospital Inc., will collaborate with New...
This $322,286 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund a study by The Johns Hopkins University to advance health equity in the use of novel treatments for Alzheimer's disease and related dementias (ADRD). The study will have two phases. In the planning phase (R61), the researchers will conduct focus groups with diverse individuals affected by ADRD to understand their medication decision-making processes. They will then design discrete...

This federal Project Grant award, provided by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), aims to develop and apply advanced statistical methods to improve scientific inferences in Alzheimer's disease (AD) research. The key products and services to be delivered through this $455,274 award made to The Johns Hopkins University include:

  1. Developing efficient and statistically proper methods to better model, estimate, and predict the risk of AD incidence and longitudinal biomarker outcomes. This includes approaches to handle age-specific prevalent cases, analyze age at biomarker positivity and time to clinical symptom onset, and model biomarker trajectories prior to symptom emergence.

  2. Applying these methodological innovations to three large-scale AD studies (BIOCARD, ABC-DS, PAC) to improve identification of high-risk individuals for targeted monitoring or treatment. The statistical advances are expected to enhance scientific inferences and enable more effective disease prediction and prevention strategies.

The award period runs from May 2025 through January 2030, reflecting the comprehensive and collaborative nature of this research effort to advance Alzheimer's disease understanding through rigorous quantitative analysis.

Generated 6/17/25, 3:43 AM